

# Mechanism of disease: The role of the epithelial cytokines in asthma

Images repository


*Please cite AstraZeneca 2022*

US-70465 Last Updated 11/22.



**EpiCentral**

UNDERSTANDING THE CENTRAL ROLE OF THE  
EPITHELIUM IN SEVERE ASTHMA AND BEYOND




## The airways are exposed to environmental insults

The airways are constantly exposed to insults such as inhaled pathogens, pollutants and aeroallergens<sup>1,2</sup>

1. Tam A, et al. *Ther Adv Respir Dis*. 2011;5:255–273; 2. Heijink IH, et al. *Allergy*. 2020;75:1902–1917






## The airway epithelium acts as a physical and immunological barrier

The airway epithelium is the first line of defense against insults such as allergens, pathogens and pollutants.<sup>1,2</sup> It provides an effective physical barrier comprising epithelial cells held together by cell-cell junctions, rendering the structure impermeable, and an immunological barrier that recognizes and controls pathogens<sup>3,4</sup>

1. Tam A, et al. *Ther Adv Respir Dis.* 2011;5:255–273; 2. Heijink IH, et al. *Allergy.* 2020;75:1902–1917; 3. Vareille M, et al. *Clin Microbiol Rev.* 2011;24:210–229; 4. Bartemes KR, Kita H. *Clin Immunol.* 2012;143:222–235






## Epithelial damage leads to physiological changes to the airways

In patients with asthma, the epithelial barrier is damaged: cell structure is compromised and there are gaps between cells.<sup>1,2</sup> These disruptions leave the cells vulnerable to environmental insults.<sup>1,2</sup> The resulting inflammation and structural changes can cause reversible airway obstruction and contribute to airway hyperresponsiveness<sup>3,4</sup>





## Epithelial damage results in the release of alarmins


Environmental insults and the subsequent epithelial damage trigger the release of epithelial cytokines, or alarmins, including IL-33, TSLP and IL-25

IL, interleukin; TSLP, thymic stromal lymphopoietin

Roan F, et al. *J Clin Invest.* 2019;129:1441–1451

Please cite **AstraZeneca 2022**. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





## Alarmins drive airway inflammation


Alarmins such as IL-33, TSLP and IL-25 drive innate and adaptive inflammatory responses and act across the spectrum of asthma inflammation in overlapping but distinct ways. Their targets include Th2 cells, ILC2s and mast cells

IL, interleukin; ILC2, type 2 innate lymphoid cell; Th, T helper; TSLP, thymic stromal lymphopietin

Roan F, et al. *J Clin Invest*. 2019;129:1441–1451

Please cite **AstraZeneca 2022**. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





## Alarmins drive inflammation from the top of the cascade

IL-33, TSLP and IL-25 can all drive allergic and non-allergic eosinophilic inflammation via effects on dendritic cells, basophils, mast cells and ILC2s.<sup>1,2</sup> Beyond T2 inflammation, TSLP can regulate the interaction between mast cells and airway smooth muscle cells.<sup>3,4</sup> TSLP has also been reported to stimulate the synthesis of collagen by lung fibroblasts, promoting airway remodeling.<sup>4</sup> Ultimately, these T2-independent effects can contribute to airway hyperresponsiveness<sup>4,5</sup>


IgE, immunoglobulin E; IL, interleukin; ILC2, type 2 innate lymphoid cell; T2, type 2; Th, T helper; TSLP, thymic stromal lymphopoietin

1. Menzies-Gow A, et al. *Respir Res.* 2020;21:268; 2. Roan F, et al. *J Clin Invest.* 2019;129:1441–1451; 3. Kaur D, et al. *Chest.* 2012;142:76–85;

4. Gauvreau GM, et al. *Expert Opin Ther Targets.* 2020;24:777–792; 5. Ishmael FT. *J Am Osteopath Assoc.* 2011;111:S11–S17

Please cite AstraZeneca 2022. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





## Th2 cells and ILC2s act downstream of the epithelial cytokines

In response to stimulation by epithelial cytokines TSLP, IL-33 and IL-25, Th2 cells and ILC2s release downstream cytokines including IL-4, IL-5 and IL-13<sup>1-3</sup>


IL, interleukin; ILC2, type 2 innate lymphoid cell; Th, T helper; TSLP, thymic stromal lymphopoietin

1. Menzies-Gow A, et al. *Respir Res.* 2020;21:268; 2. Roan F, et al. *J Clin Invest.* 2019;129:1441–1451; 3. Gauvreau GM, et al. *Expert Opin Ther Targets.* 2020;24:777–792

Please cite AstraZeneca 2022. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.







## B-cell synthesis of IgE is upregulated in response to inflammatory signaling


IL-4, released by Th2 cells in response to stimulation by epithelial cytokines, triggers immunoglobulin class switching and the production of IgE by B cells<sup>1–3</sup>

IgE, immunoglobulin E; IL, interleukin; Th, T helper

1. Menzies-Gow A, et al. *Respir Res*. 2020;21:268; 2. Roan F, et al. *J Clin Invest*. 2019;129:1441–1451; 3. Gauvreau GM, et al. *Expert Opin Ther Targets*. 2020;24:777–792

Please cite AstraZeneca 2022. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





## TSLP can influence mast cells, contributing to airway hyperresponsiveness

As part of its T2-independent effects, TSLP can regulate the crosstalk between mast cells and airway smooth muscle by stimulating the release of signaling molecules.<sup>1</sup> In doing so, TSLP-mediated mast cell-airway smooth muscle crosstalk can contribute to airway hyperresponsiveness<sup>2</sup> – a cardinal feature of asthma<sup>3</sup>

T2, type 2; TSLP, thymic stromal lymphopoietin

1. Kaur D, et al. *Chest*. 2012;142:76–85; 2. Gauvreau GM, et al. *Expert Opin Ther Targets*. 2020;24:777–792; 3. Chapman DG, Irvin CG. *Clin Exp Allergy*. 2015;45:706–719

Please cite AstraZeneca 2022. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





## Epithelial cytokines drive pathophysiological changes to the airways in patients with asthma

As a result of inflammatory signaling downstream of the epithelial cytokines TSLP, IL-33 and IL-25, airway inflammation can ultimately lead to edema, mucus hypersecretion, airway hyperresponsiveness and bronchoconstriction<sup>1-5</sup>

IL, interleukin; TSLP, thymic stromal lymphopoietin

1. Bartemes KR, Kita H. *Clin Immunol*. 2012;143:222–235; 2. Marone G, et al. *Front Pharmacol*. 2019;10:1387; 3. Gauvreau GM, et al. *Expert Opin Ther Targets*. 2020;24:777–792; 4. Sumi Y, Hamid Q. *Allergol Int*. 2007;56:341–348; 5. Porsbjerg CM, et al. *Eur Respir J*. 2020;56:2000260

Please cite AstraZeneca 2022. US-70465 Last Updated 11/22. ©2022 AstraZeneca. All Rights Reserved. This information is intended for healthcare professionals only. EpiCentral is sponsored by Amgen and AstraZeneca.





Clinical features of asthma are associated with the downstream effects of epithelial cytokines

Pathophysiological changes occurring in the airways, as a result of epithelial cytokine-mediated inflammatory signaling, can drive clinical features of asthma including cough, wheeze, shortness of breath and increased risk of severe asthma exacerbations<sup>1,2</sup>

1. Porsbjerg CM, et al. *Eur Respir J.* 2020;56:2000260; 2. Heijink IH, et al. *Allergy.* 2020;75:1902–1917

